Cedar Mountain Advisors
VIR icon

Cedar Mountain Advisors’s Vir Biotechnology VIR Stock Holding History

Cedar Mountain Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13K Hold
101
– – ﹤0.01% 892
2026
Q2 		$1.03K Hold
101
– – ﹤0.01% 946
2026
Q1 		$905 Hold
101
– – ﹤0.01% 925
2025
Q4 		$609 Hold
101
– – ﹤0.01% 580
2025
Q3 		$577 Buy
+101
New +$516 ﹤0.01% 590

Other funds holding VIR

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Foster Group
Foster Group West Des Moines, Iowa $3.68B AUM 13.84% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Cedar Mountain Advisors's VIR Position: Q3 2026 in Review

Cedar Mountain Advisors held its Vir Biotechnology (VIR) position steady in Q3 2026 at 101 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

Cedar Mountain Advisors first reported a position in VIR in Q3 2025 and has held it in 5 quarters since. 25 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • Cedar Mountain Advisors held 101 shares of Vir Biotechnology worth $1.13K as of Q3 2026.
  • Cedar Mountain Advisors left its Vir Biotechnology share count unchanged in Q3 2026.
  • Vir Biotechnology made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #892 holding.
  • Cedar Mountain Advisors first reported a position in Vir Biotechnology in Q3 2025 and has held it in 5 quarters since.
  • 25 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.